# A Multicenter, Prospective, Phase II Study of Zanubrutinib for Maintenance in Patients With Mantle Cell Lymphoma

> **NCT06341556** · PHASE2 · RECRUITING · sponsor: **Fudan University** · enrollment: 52 (estimated)

## Conditions studied

- Mantle Cell Lymphoma
- Maintenance Therapy

## Interventions

- **DRUG:** Zanubrutinib

## Key facts

- **NCT ID:** NCT06341556
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-24
- **Primary completion:** 2026-03
- **Final completion:** 2028-06
- **Target enrollment:** 52 (ESTIMATED)
- **Last updated:** 2024-09-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06341556

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06341556, "A Multicenter, Prospective, Phase II Study of Zanubrutinib for Maintenance in Patients With Mantle Cell Lymphoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06341556. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*